Magnesium L-Threonate for Brain Health: What Human Trials Actually Show

Magnesium L-threonate has promising but still preliminary evidence for cognition. A recent six-week randomized trial tested 2 g/day of Magtein alone in 100 adults aged 18–45 who reported dissatisfied sleep. It found a small between-group advantage on the NIH Total Cognition Composite and reaction time, but no difference on Raven's matrices and no improvement in objective sleep measures (PMID 41601871). The study was funded by Threotech, which supplied the product and participated in study design. Other positive trials do not answer exactly the same question. One studied the investigational L-threonic acid magnesium salt MMFS-01 in 44 adults aged 50–70 with cognitive impairment (PMID 26519439). Another tested a combination containing magnesium L-threonate, phosphatidylserine, and vitamins C and D in 109 healthy adults for 30 days, so its results cannot be assigned to magnesium L-threonate alone (PMID 36558392). A separate trial in breast-cancer survivors found no improvement over placebo in cognition, sleep, mood, or pain (PMID 37520407). The most defensible conclusion is that magnesium L-threonate may affect some cognitive test outcomes in selected populations, but the evidence is too limited to promise general brain-health improvement, prevention of cognitive decline, or treatment of a neurological condition. A 2024 systematic review found too few magnesium-supplement RCTs to draw firm conclusions about cognitive effects (PMID 39009081). This page is educational and not medical advice.

The mechanistic case comes mainly from animals. In rats, Slutsky and colleagues reported that magnesium L-threonate raised brain magnesium and changed measures of synaptic plasticity, learning, and memory (PMID 20152124). Additional rat and Alzheimer-model mouse studies reported region-specific plasticity and synaptic findings (PMIDs 22016520 and 25213836). Those studies do not establish the same effects in humans. The human trials on this page did not directly demonstrate blood-brain-barrier transport, a rise in cerebrospinal-fluid magnesium, or increased synaptic density in people. HAA therefore does not call magnesium L-threonate the only magnesium form that crosses the human blood-brain barrier and does not translate animal mechanisms into a clinical promise.

First verify the Supplement Facts panel, not the marketing headline. The label should distinguish the weight of magnesium L-threonate from the much smaller amount of elemental magnesium. Compare serving size, elemental magnesium, other ingredients, and the date and source of any price shown. Do not assume that the phrase “clinically studied” means the finished retail product was tested, or that animal brain-magnesium findings prove a human cognitive benefit. Product order on this page is not a clinical ranking. We found no head-to-head trial showing that one of these retail products improves cognition more than the other.